Decreased plasma sRAGE levels in COPD: Influence of oxygen therapy

European Journal of Clinical Investigation

Volumn 42, Issue 8, 2012, Pages 807-814

  Gopal, Poornima ^a   Rutten, Erica P A ^b   Dentener, Mieke A ^a   Wouters, Emiel F M ^a,b   Reynaert, Niki L ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Centre of Expertise for Chronic Organ Failure (CIRO)   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Long term oxygen therapy; Lung function; N (carboxymethyl) lysine; SRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; LYSINE DERIVATIVE; N (CARBOXYMETHYL)LYSINE; UNCLASSIFIED DRUG;

ADULT; AGE; AMINO ACID BLOOD LEVEL; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INFLAMMATION; LONG TERM CARE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MALE; MIDDLE AGED; OXIDATIVE STRESS; OXYGEN INHALATION THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, IMMUNOLOGIC; RESPIRATORY FUNCTION TESTS; TIME FACTORS;

EID: 84864008347     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02646.x     Document Type: Article

References (39)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
2. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412.
3. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010;65:930-6.
4. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-13.
5. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-86.
6. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
7. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001;50:2792-808.
8. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-35.
9. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-31.
10. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005;7:R817-24.
11. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005;23:1725-9.
12. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25:1032-7.
13. Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T et al. Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML). Cardiovasc Diabetol 2009;8:45.
14. Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end products in chronic obstructive pulmonary disease. Eur Respir J 2010;37:516-22.
15. Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res 2011;12:37.
16. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008;22:3716-27.
17. Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, Makita K et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells 2004;9:165-74.
18. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008;172:583-91.
19. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H et al. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005;18:1385-96.
20. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickersham N et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008;63:1083-9.
21. Queisser MA, Kouri FM, Konigshoff M, Wygrecka M, Schubert U, Eickelberg O et al. Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 2008;39:337-45.
22. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:917-27.
23. Yanbaeva DG, Dentener MA, Spruit MA, Houwing-Duistermaat JJ, Kotz D, Passos VL et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet 2009;10:23.
24. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
25. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007;6:9.
26. Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG et al. Soluble RAGE is deficient in neutrophilic asthma and chronic obstructive pulmonary disease. Eur Respir J 2011, ePub ahead of print.
27. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-35.
28. Nakamura K, Adachi H, Matsui T, Kurita Y, Takeuchi M, Yamagishi S. Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism 2009;58:421-5.
29. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009;52:705-14.
30. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007;43:511-8.
31. Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007;8:1138-43.
32. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999;274:31740-9.
33. Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 2007;7:188-90.
34. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006;55:1227-31.
35. Kanazawa H, Kodama T, Asai K, Matsumura S, Hirata K. Increased levels of N(epsilon)-(carboxymethyl)lysine in epithelial lining fluid from peripheral airways in patients with chronic obstructive pulmonary disease: a pilot study. Clin Sci (Lond) 2010;119:143-9.
36. Kluchova Z, Petrasova D, Joppa P, Dorkova Z, Tkacova R. The association between oxidative stress and obstructive lung impairment in patients with COPD. Physiol Res 2007;56:51-6.
37. Lizotte PP, Hanford LE, Enghild JJ, Nozik-Grayck E, Giles BL, Oury TD. Developmental expression of the receptor for advanced glycation end-products (RAGE) and its response to hyperoxia in the neonatal rat lung. BMC Dev Biol 2007;7:15.
38. Foschino Barbaro MP, Serviddio G, Resta O, Rollo T, Tamborra R, Elisiana Carpagnano G et al. Oxygen therapy at low flow causes oxidative stress in chronic obstructive pulmonary disease: prevention by N-acetyl cysteine. Free Radic Res 2005;39:1111-8.
39. Zouaoui Boudjeltia K, Tragas G, Babar S, Moscariello A, Nuyens V, Van Antwerpen P et al. Effects of oxygen therapy on systemic inflammation and myeloperoxidase modified LDL in hypoxemic COPD patients. Atherosclerosis 2009;205:360-2.